NIH grant fuels NYU Langone efforts to accelerate medical research discoveries
· News-MedicalNYU Langone Health has been awarded a nearly $70 million, seven-year renewal grant from the National Institutes of Health (NIH) to fund its Clinical and Translational Science Institute (CTSI). The award is the highest level of funding available nationally under NIH's Clinical and Translational Science Awards (CTSA) Program.
The CTSI provides scientists and clinicians with biostatistics support, large-scale patient data infrastructure, clinical trial networks, and career development programs. These resources would be prohibitively expensive for any single department to build independently. Since its founding in 2009, the institute has supported nearly 5,000 requests, more than half led by early-career investigators, underscoring the CTSI's role as a pipeline for developing the next generation of translational scientists. The projects have generated more than 1,500 grants and more than 1,500 peer-reviewed publications contributing to advances in patient care, public health, and health policy.
With the renewal, NYU Langone will expand this work over the next seven years through five priorities: deepening community-engaged research, broadening access to health informatics tools, training the full spectrum of the research workforce, forging regional and national collaborations, and accelerating clinical trial start-up and completion.
NYU Langone's large network, including the Family Health Centers, NYC Health + Hospitals, and all 11 schools and colleges of New York University, enables the CTSI to engage a uniquely wide-ranging urban population, positioning New York City as a living laboratory for translational research.
"Translational research is central to our mission at NYU Langone," said Dafna Bar-Sagi, PhD, chief scientific officer and executive vice president and vice dean for science. "The CTSI is a critical institutional engine that allows us to turn scientific discovery into better care for patients across New York City and beyond. This award reflects both the strength of our research enterprise and our commitment to ensuring that innovation reaches patients quickly, equitably, and at scale."
Source: